Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 31 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Olaparib in addition to abiraterone for metastatic castration-resistant prostate cancer – First line	Abiraterone acetate (Zytiga; Yonsa) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Prostate cancer	Male Reproductive Cancer	2020	View \| Download
Pembrolizumab (Keytruda) for metastatic castration‐resistant prostate	Pembrolizumab (Keytruda; MK-3475)	Prostate cancer	Male Reproductive Cancer	2017	View \| Download
Pembrolizumab in addition to docetaxel for chemotherapy-naive metastatic castration-resistant prostate cancer – second line	Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Pembrolizumab (Keytruda; MK-3475)	Prostate cancer	Male Reproductive Cancer	2020	View \| Download
Pembrolizumab in combination with olaparib for anti-hormone and chemotherapy failure metastatic castration-resistant prostate cancer – third line	Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475)	Prostate cancer	Male Reproductive Cancer	2020	View \| Download
Pembrolizumab with Enzalutamide and androgen deprivation therapy for the treatment of metastatic hormone sensitive prostate cancer	Androgen deprivation therapy , Enzalutamide (Xtandi; MDV3100) , Pembrolizumab (Keytruda; MK-3475)	Prostate cancer	Male Reproductive Cancer	2022	View \| Download
Pembrolizumab with enzalutamide for treating metastatic castration-resistant prostate cancer	Enzalutamide (Xtandi; MDV3100) , Pembrolizumab (Keytruda; MK-3475)	Prostate cancer	Male Reproductive Cancer	2022	View \| Download
Relugolix for treating advanced hormone-sensitive prostate cancer	Relugolix (TAK-385)	Prostate cancer	Male Reproductive Cancer	2022	View \| Download
Rucaparib for metastatic castration-resistant prostate cancer associated with homologous recombination deficiency	Rucaparib (Rubraca; PF-1367338)	Prostate cancer	Male Reproductive Cancer	2022	View \| Download
Talazoparib in addition to enzalutamide for metastatic castration-resistant prostate cancer	Enzalutamide (Xtandi; MDV3100) , Talazoparib (MDV3800; BMN-673; Talzenna; talazoparib tosylate)	Prostate cancer	Male Reproductive Cancer	2021	View \| Download
Talazoparib with enzalutamide for previously untreated homologous recombination repair-mutated metastatic hormonal-sensitive prostate cancer	Enzalutamide (Xtandi; MDV3100) , Talazoparib (MDV3800; BMN-673; Talzenna; talazoparib tosylate)	Prostate cancer	Male Reproductive Cancer	2024	View \| Download